To OMX Nordic Exchange and the press Announcement no. 19/2008 Pharmexa A/S - Minutes of extraordinary general meeting Minutes of extraordinary general meeting of Pharmexa A/S The proposals by the Board of Directors to reduce the share capital at a price of DKK 40 per share by transfer to a special fund that may only be used as resolved by the general meeting, and to change the face value of the company's shares as well as the minimum subscription price was adopted. The company's creditors will be requested to file their proofs of claim against the company within a period of three months. The capital reduction and the change of face value of the shares, etc. will only be implemented upon expiry of the three-month period. Hørsholm, 1 July 2008 Jakob Schmidt Chief Executive Officer For further information: Jakob Schmidt, Chief Executive Officer, tel. +45 4516 2525 Claude Mikkelsen, Vice President, Corporate Affairs and Communication, tel. +45 4516 2525 or +45 4060 2558 For the editors: Pharmexa A/S is a development stage company in the field of active immunotherapy. Pharmexa's proprietary technology platforms are broadly applicable, allowing the company to address critical targets in cancer and chronic diseases, as well as serious infectious diseases such as HIV, influenza, hepatitis and malaria. Collaborative agreements include H. Lundbeck, Bavarian Nordic and Ichor Medical Systems. With operations in Denmark and USA, Pharmexa employs approximately 40 employees and is listed on the Copenhagen Stock Exchange under the trading symbol PHARMX.